Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment

References

• Swerdllow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
   Google Scholar
• Jaffe ES, Harris NL, Vardiman J, et al. Hematopathology. Philadelphia, PA: Elsevier Health Sciences; 2011.
   Google Scholar
• Kim JM, Ko YH, Lee SS, et al. WHO classification of malignant lymphomas in Korea: report of the third nationwide study. Korean J Pathol 2011;45:254–260.
   Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494–5502.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011;117:4836–4843.
   PubMed Web of Science ®Google Scholar
• Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78–84.
   PubMed Web of Science ®Google Scholar
• Hovelmeyer N, Reissig S, Xuan NT, et al. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur J Immunol 2011;41:595–601.
   PubMed Web of Science ®Google Scholar
• Giulino L, Mathew S, Ballon G, et al. A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma. Blood 2011;117:4852–4854.
   PubMed Web of Science ®Google Scholar
• Kelly C, Shields MD, Elborn JS, et al. A20 regulation of nuclear factor-kappaB: perspectives for inflammatory lung disease. Am J Respir Cell Mol Biol 2011;44:743–748.
   PubMed Web of Science ®Google Scholar
• Matmati M, Jacques P, Maelfait J, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011;43:908–912.
   PubMed Web of Science ®Google Scholar
• Adrianto I, Wen F, Templeton A, et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet 2011;43:253–258.
   PubMed Web of Science ®Google Scholar
• Huang H, Tang QZ, Wang AB, et al. Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension 2010;56:232–239.
   PubMed Web of Science ®Google Scholar
• Damrauer SM, Studer P, da Silva CG, et al. A20 modulates lipid metabolism and energy production to promote liver regeneration. PLoS One 2011;6:e17715.
   Web of Science ®Google Scholar
• Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009;206:981–989.
   PubMed Web of Science ®Google Scholar
• Atlas of genetics and cytogenetics in oncology. and haematology . Available from: http://AtlasGeneticsOncology.org
   Google Scholar
• Berglund M, Enblad G, Flordal E, et al. Chromosomal imbalances in diffuse large B-cell lymphoma detected by comparative genomic hybridization. Mod Pathol 2002;15:807–816.
   PubMed Web of Science ®Google Scholar
• Bea S, Colomo L, Lopez-Guillermo A, et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol 2004;22:3498–3506.
   PubMed Web of Science ®Google Scholar
• Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009;114:2467–2475.
   PubMed Web of Science ®Google Scholar
• Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712–716.
   PubMed Web of Science ®Google Scholar
• Chanudet E, Huang Y, Ichimura K, et al. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 2010;24:483–487.
   PubMed Web of Science ®Google Scholar
• Braun FC, Grabarczyk P, Mobs M, et al. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sezary syndrome. Leukemia 2011;25:1494–1501.
   PubMed Web of Science ®Google Scholar
• Dong G, Chanudet E, Zeng N, et al. A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. Clin Cancer Res 2011;17:1440–1451.
   PubMed Web of Science ®Google Scholar
• Yoon SO, Kim WY, Go H, et al. Class III beta-tubulin shows unique expression patterns in a variety of neoplastic and non-neoplastic lymphoproliferative disorders. Am J Surg Pathol 2010;34:645–655.
   PubMed Web of Science ®Google Scholar
• Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology 2008;53:205–217.
   PubMed Web of Science ®Google Scholar
• Kim WY, Jeon YK, Kim TM, et al. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol 2009;20:1688–1696.
   PubMed Web of Science ®Google Scholar
• Go H, Cho HJ, Paik JH, et al. Thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a clinicopathological and genetic analysis of six cases. Leuk Lymphoma 2011;52:2276–2283.
   PubMed Web of Science ®Google Scholar
• Wotherspoon AC, Finn TM, Isaacson PG. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood 1995;85:2000–2004.
   PubMed Web of Science ®Google Scholar
• Hirsch B, Grunbaum M, Wagner F, et al. A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology. Histopathology 2012;60:E19–E27.
   PubMed Web of Science ®Google Scholar
• Vendrell JA, Ghayad S, Ben-Larbi S, et al. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 2007;26:4656–4667.
   Google Scholar
• Hjelmeland AB, Wu Q, Wickman S, et al. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol 2010;8:e1000319.
   PubMed Web of Science ®Google Scholar
• Lademann U, Kallunki T, Jäättelä M. A20 zinc finger protein inhibits TNF-induced apoptosis and stress response early in the signaling cascades and independently of binding to TRAF2 or 14-3-3 proteins. Cell Death Differ 2001;8:265.
   PubMed Web of Science ®Google Scholar
• Dong B, Lv G, Wang Q, et al. Targeting A20 enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2012;418:433–438.
   PubMed Web of Science ®Google Scholar
• Guo Q, Dong H, Liu X, et al. A20 is overexpressed in glioma cells and may serve as a potential therapeutic target. Expert Opin Ther Targets 2009;13:733–741.
   PubMed Web of Science ®Google Scholar
• Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012;12:121–132.
   PubMed Web of Science ®Google Scholar
• Kim WS, Honma K, Karnan S, et al. Genome-wide array- based comparative genomic hybridization of ocular marginal zone B cell lymphoma: comparison with pulmonary and nodal marginal zone B cell lymphoma. Genes Chromosomes Cancer 2007;46: 776–783.
   PubMed Web of Science ®Google Scholar
• Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosomes Cancer 2008;47:1–7.
   PubMed Web of Science ®Google Scholar
• Gualco G, Weiss LM, Bacchi CE. MUM1/IRF4: a review. Appl Immunohistochem Mol Morphol 2010;18:301–310.
   PubMedGoogle Scholar
• Saez AI, Saez AJ, Artiga MJ, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 2004;164:613–622.
   PubMed Web of Science ®Google Scholar
• Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464–470.
   PubMed Web of Science ®Google Scholar
• De Mello CA, De Andrade VP, De Lima VC, et al. Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma. Leuk Lymphoma 2011;52: 1495–1503.
   PubMed Web of Science ®Google Scholar